Effects of oncostatin M and tamoxifen on human melanoma cells

Melanoma Research

Volumn 8, Issue 3, 1998, Pages 221-226

  Gibbs, P ^a   Chen, Q ^a   Robinson, W A ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Melanoma; Oncostatin M; Tamoxifen

Indexed keywords

ONCOSTATIN M; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; DOSE RESPONSE; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MELANOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; HUMANS; MELANOMA; ONCOSTATIN M; PEPTIDES; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0031838881     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199806000-00004     Document Type: Article

References (25)

1. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997; 15: 797-819.
2. Mosley B, De Imus C, Friend D, et al. Dual oncostatin M (OSM) receptors. Cloning and characterisation of an alternative signalling subunit conferring OSM-specific receptor activation. J Biol Chem 1996; 271: 32635-32643.
3. Zarling J, Shoyab M, Marquardt H, et al. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci USA 1986; 1: 9739-9743.
4. Liu J, Wallace PM, Vestal RE. Oncostatin M inhibits breast cancer cell growth. Proc Annu Meet Am Assoc Cancer Res 1995; 36: A1529(abstract).
5. Horn D, Fitzpatrick W, Gompper P, et al. Regulation of cell growth by recombinant oncostatin M. Growth Factors 1990; 2: 157-165.
6. Nair BC, DeVico AL, Nakamura S, et al. Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science 1992; 255: 1430-1432.
7. Zhang X, Gu J, Lu XY, et al. Ciliary neurotrophic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 1994; 179: 1337-1342.
8. Lu C, Rak J, Kobayashi H, Kerbel R. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced stage lesions. Cancer Res 1993; 53: 2708-2711.
9. Brown T, Lioubin M, Marquardt H. Purification and characterisation of cytostatic lymphokines produced by activated human T-lymphocytes: synergistic antiproliferative activity of TGFβ1, interferon γ and oncostatin M for human melanoma cells. J Immunol 1987; 139: 2877-2983.
10. Heymann D, Godard A, Raher S, et al. Human interleukin for DA cells/leukemia inhibitory factor and oncostatin M enhance the membrane expression of intracellular adhesion molecule-1 on melanoma cells but not the shedding of its soluble form. Cytokine 1995; 7: 111-117.
11. Richards C, Shoyab M, Brown T, et al. Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol 1993; 150: 5596-5603.
12. Gelmann E. Tamoxifen for the treatment of malignancies other than breast and endometrial cancer. Semin Oncol 1997; 24(suppl 1): 65-70.
13. Miller J, Gee J, Price A, et al. Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Melanoma Res 1997; 7: 197-208.
14. Piantelli M, Maggiano N, Ricci R, et al. Tamoxifen and quecertin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol 1995; 105: 248-253.
15. Jones J, Albright K, Winski P, et al. Loss of a high affinity nuclear anti-estrogen binding site confers loss of synergy between cisplatin and tamoxifen in human melanoma cells. Proc Annu Meet Am Assoc Cancer Res 1996; 37: A243(abstract).
16. Dewhurst L, Gee J, Rennie I, et al. Tamoxifen, 17β-estradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. Br J Cancer 1997; 75: 860-868.
17. Butta A, MacLennan K, Flanders K, et al. Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261-4264.
18. Gelmann E. Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog. J Natl Cancer Inst 1996; 88: 224-226.
19. Van Belle P, Rodeck U, Nuamah I, et al. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 1996; 148: 1887-1894.
20. Schmid P, Itin P, Rufli T. In situ analysis of transforming growth factor-betas (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis 1995; 16: 1499-1503.
21. McClay E, Jones J. Tamoxifen (TAM) resistance is associated with decreased p27 expression and reduction in TGF-β1 production. Proc Annu Meet Am Assoc Cancer Res 1997; 37: A4193(abstract).
22. Treon S, Teoh G, Urashima M, et al. Anti-estrogens as agents for the treatment of multiple myeloma. Proc ASCO 1997; 16: A35(abstract).
23. McDonald VL, Dick KO, Malik N, et al. Selection and characterisation of a variant of human melanoma cell line A375 resistant to growth inhibitory effects of oncostatin M (OSM): co-resistant to interleukin 6 (IL-6). Growth factors 1993; 9: 167-175.
24. Kerbel RS. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am J Pathol 1992; 14: 519-524.
25. Modur V, Feldbaus M, Weyrich A, et al. Oncostatin M is a proinflammatory mediator. J Clin Invest 1997; 100: 158-168.